journal
MENU ▼
Read by QxMD icon Read
search

Current Research in Translational Medicine

journal
https://www.readbyqxmd.com/read/30274738/burden-of-cytomegalovirus-disease-in-allogeneic-hematopoietic-cell-transplant-recipients-a-national-matched-cohort-study-in-an-inpatient-setting
#1
Z Hakimi, S Ferchichi, S Aballea, I Odeyemi, M Toumi, M English, I Yakoub-Agha
PURPOSE OF THE STUDY: No studies have compared the risk of mortality or graft-versus-host disease, in an inpatient setting in France, in allogeneic hematopoietic cell transplant recipients who develop cytomegalovirus disease with those who do not. This study assessed the impact of cytomegalovirus disease on clinical outcomes and healthcare resource utilization in allogeneic hematopoietic cell transplant recipients using the French Programme de Médicalisation des Systèmes d'Information database...
September 28, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/30217555/diagnostic-accuracy-of-interleukin-22-and-adenosine-deaminase-for-tuberculous-pleural-effusions
#2
Junyun He, Rui Zhang, Yongchun Shen, Chun Wan, Ni Zeng, Jiangyue Qin, Panwen Tian, Lei Chen
OBJECTIVE: Reliable markers for accurately diagnosing tuberculous pleural effusions (TPE) are needed. This study sought to investigate the diagnostic potential of pleural interleukin-22 (IL-22) and compare it with the performance of adenosine deaminase (ADA). METHOD: This prospective study involved 49 patients with TPE and 60 patients with pleural effusion of other causes. Pleural levels of IL-22 and ADA were determined, respectively, using ELISA or an enzymatic method...
September 11, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/30206046/site-specific-diagnostic-yield-of-endoscopic-biopsies-in-gastrointestinal-graft-versus-host-disease-a-tertiary-care-center-experience
#3
Fady Daniel, Lara Hassoun, Mohammad Husni, Alaa Sharara, Assad Soweid, Kassem Barada, Basel Haffar, Radwan Massoud, Yasser Shaib, Jana Al-Hashash, Ali Bazarbachi, Jean El Cheikh
BACKGROUND: Gastrointestinal (GI) graft versus host disease (GVHD) occurs in up to 40% of patients undergoing allogenic hematopoietic stem cell transplantation (HSCT). However, the optimal endoscopic approach is still unclear and the area of the GI tract with the highest diagnostic yield is still a topic of debate. OBJECTIVE: We compared the diagnostic yield of different anatomic site biopsies in the diagnosis of GI GVHD and assessed the correlation of endoscopic findings with histopathology...
September 8, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/30206045/scoring-system-based-on-post-transplant-complications-in-patients-after-allogeneic-hematopoietic-cell-transplantation-for-myelodysplastic-syndrome-a-study-from-the-sfgm-tc
#4
Alexis Caulier, Elodie Drumez, Jordan Gauthier, Marie Robin, Didier Blaise, Yves Beguin, Mauricette Michallet, Patrice Chevallier, Jacques-Olivier Bay, Stéphane Vigouroux, Yohan Desbrosses, Jérôme Cornillon, Stéphanie Nguyen, Charles Dauriac, Régis Peffault de Latour, Bruno Lioure, Pierre-Simon Rohrlich, Martin Carré, Jean-Henri Bourhis, Anne Huynh, Felipe Suarez, Federico Garnier, Alain Duhamel, Ibrahim Yakoub-Agha
PURPOSE: We developed a prognostic scoring system to evaluate the prognosis of myelodysplastic syndrome (MDS) patients surviving more than 100 days allogeneic hematopoietic cell transplantation after (allo-HCT). PATIENTS AND METHODS: We performed a landmark analysis on a derivation cohort of 393 cases to identify prognostic factors for 3-year overall survival. Potential predictor variables included demographic and clinical data, transplantation modalities and early post-transplant complications...
September 8, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/30104160/adipose-tissue-derived-mesenchymal-stromal-cells-for-clinical-application-an-efficient-isolation-approach
#5
D Lisini, S Nava, S Pogliani, M A Avanzini, E Lenta, G Bedini, M Mantelli, L Pecciarini, S Croce, G Boncoraglio, R Maccario, E A Parati, S Frigerio
PURPOSE OF THE STUDY: Mesenchymal stromal cells (MSCs) are considered a promising tool for cell therapy approaches. The translation of research-based cell culture protocols into procedures that comply with Good Manufacturing Practice (GMP) is critical. The aim of this study was to design a new method for the expansion of MSCs from Adipose Tissue (AT-MSCs) in compliance with GMP, without enzymatic tissue digestion and without the use of animal proteins as source of growth factors. PATIENTS AND METHODS: MSCs were expanded from 10 periumbilical biopsies...
August 10, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/30097215/clonal-evolution-of-myelofibrosis-treated-with-hematopoietic-transplantation-using-ruxolitinib-for-chronic-gvhd-a-case-report
#6
L Fouillet, E Daguenet, F Schein, E Tavernier, P Flandrin-Gresta, J Cornillon
Deciphering the mutational patterns and/or the biomarkers that might predict clinical response in patients with myelofibrosis is primordial to make treatment decisions. In this report, we discuss the clinical history, pathological evaluation, and genomics findings in a patient with JAK2-positive myelofibrosis who developed a secondary myelodysplasia after hematopoietic stem cell transplantation and JAK1/2 inhibitor treatment. Using next-generation sequencing, a paired comparison of relapse-specific versus primary tumour mutations highlighted the dynamic clonal evolution at relapse, showing concurrently the complete eradication of the JAK2-positive clone and the expansion of a second JAK2-negative clone with additional mutations...
August 7, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/30191811/acute-polyradiculopathy-secondary-to-idelalisib-in-relapsed-classical-hodgkin-s-lymphoma
#7
S Barbieux, E M Boyle, C Baillet, H Demarquette, P Vermersch, F Morschhauser, C Herbaux
Patients with relapsed or refractory Hodgkin's lymphoma are likely incurable with standard treatment. Idelalisib, a delta-isoform specific Phosphatidyl-inositol-3-kinase (PI3K) inhibitor has shown its efficacy in other hematopoietic B malignancies. We report the case of a 51-years old patient with relapsed and refractory Hodgkin's Lymphoma receiving idelalisib after several regimens of chemotherapy. He achieved a good partial response for several months, unfortunately, idelalisib had to be stopped because of the onset of a severe polyradiculoneuritis attributed to this treatment...
September 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/30108026/schnitzler-syndrome-co-occurring-with-idiopathic-multicentric-castleman-disease-that-responds-to-anti-il-1-therapy-a-case-report-and-clue-to-pathophysiology
#8
Simon Soudet, David Fajgenbaum, Claire Delattre, Alexandra Forestier, Eric Hachulla, Pierre Yves Hatron, David Launay, Louis Terriou
Patients with HHV-8-negative/idiopathic multicentric Castleman disease (iMCD) experience systemic inflammatory symptoms and polyclonal lymphoproliferation due to an unknown etiology. Schnitzler's syndrome (SS) is characterized by recurrent urticarial rash, monoclonal IgM gammopathy, and other clinical signs of inflammation. To our knowledge, we report the first case of iMCD associated with SS and the fourth case of anakinra inducing a complete response for an iMCD patient. A forty-four year old woman with a history of a recurrent urticarial rash, presented to our hospital complaining of 6 months of night sweats, fever, chronic urticaria, iliac bone pain, and generalized lymphadenopathy...
September 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/30108025/association-between-type-i-interferon-and-depletion-and-dysfunction-of-endothelial-progenitor-cells-in-c57bl-6-mice-deficient-in-both-apolipoprotein-e-and-fas-ligand
#9
Linyu Geng, Shiying Wang, Xia Li, Dandan Wang, Haifeng Chen, Jinyun Chen, Yue Sun, Weiwei Chen, Genhong Yao, Xiang Gao, Wanjun Chen, Songtao Shi, Xuebing Feng, Lingyun Sun
Patients with systemic lupus erythematosus (SLE) have a tremendously increased risk for cardiovascular disease (CVD), which could not be accounted in entirety by traditional Framingham risk factors. To study whether the accelerated atherosclerosis in SLE patients is mediated by type I interferon (IFN-I) through the regulation of endothelial progenitor cells (EPCs), we created a line of C57BL/6 mice with deficiency in both apolipoprotein E (ApoE-/-) and fas ligand (FasL-/-, gld.). As expected, the resultant gld...
September 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29540329/assessment-of-egfr-mutation-status-in-tunisian-patients-with-pulmonary-adenocarcinoma
#10
A Arfaoui Toumi, A Blel, R Aloui, H Zaibi, M Ksentinini, M S Boudaya, N Znaidi, Y Zidi, H Aouina, S Rammeh Rommani
BACKGROUND: Despite recent advances, non-small cell lung cancer carries a grim prognosis. For appropriate treatment selection, the updated guidelines recommend broad molecular profiling for all patients with pulmonary adenocarcinoma. Precise histological subtyping and targeted epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing are mandatory. METHODS: Herein, we assessed the EGFR mutation status of 26 formalin fixed-paraffin embedded (FFPE) samples of lung adenocarcinoma...
September 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29525419/infusion-of-in-vivo-expanded-cord-blood-lymphocytes-a-new-strategy-to-control-residual-disease
#11
LETTER
S Lamure, J Delage, L Vincent, N Fegueux, L Zhao-Yang, G Cartron, P Ceballos, J De Vos
No abstract text is available yet for this article.
September 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29691200/crispr-cas9-genome-editing-fueling-the-revolution-in-cancer-immunotherapy
#12
REVIEW
Xiaojun Liu, Yangbing Zhao
The development of genomic editing technologies expands the landscape of T cell engineering for adoptive cell therapy. Among the multiple tools that can be used, CRISPR/Cas9 has been shown to be relatively easy to use, simple to design and cost effective with highly efficient multiplex genome engineering capabilities. Allogeneic universal chimeric antigen receptor (CAR) T cells can be produced by disrupting T cell receptor (TCR) and beta-2-microglobulin (B2M) in CAR T cells or by directly knocking in a CAR at the disrupted TRAC locus...
May 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29685844/car-t-cells-a-john-von-neumann-legacy
#13
EDITORIAL
Bruno Quesnel
No abstract text is available yet for this article.
May 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29685843/clinical-units-to-set-up-chimeric-antigen-receptor-t-cell-therapy-car-t-cells-based-on-the-recommendations-of-the-francophone-society-of-bone-marrow-transplantation-and-cellular-therapy-sfgm-tc
#14
Ibrahim Yakoub-Agha
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) hold its eighth practice harmonization workshops on September 2017. In a workshop dedicated to chimeric antigen receptor T-cell therapy (CAR T-cells), the society issued recommendations regarding the prerequisite for hematopoietic cellular therapy programs to set up CAR T-cell therapy. In this article we focused on the prerequisite needed, in France, for a hematopoietic transplantation unit to start a CAR T-cell program with industrial manufactured cells within investigational products or after market access authorization...
May 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29656949/beginning-the-car-t-cell-therapy-revolution-in-the-us-and-eu
#15
LETTER
Stephan Grupp
No abstract text is available yet for this article.
May 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29655962/novel-targets-and-technologies-for-car-t-cells-in-multiple-myeloma-and-acute-myeloid-leukemia
#16
EDITORIAL
Sabrina Prommersberger, Hardikkumar Jetani, Sophia Danhof, Razieh Monjezi, Thomas Nerreter, Julia Beckmann, Herrmann Einsele, Michael Hudecek
No abstract text is available yet for this article.
May 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29655961/chimeric-antigen-receptor-t-cell-therapy-for-non-hodgkin-lymphoma
#17
REVIEW
Armin Ghobadi
Non-Hodgkin Lymphoma (NHL) is the most common hematologic malignancy. More than 20,000 people in United States, more than 37,000 people in Europe and more than 199,000 people worldwide die of NHL every year. Recent advances in immunotherapeutic approaches for cancer have resulted in development of new classes of very effective immunotherapeutic approaches including chimeric antigen receptor T (CAR-T) cell therapy that are designed to bypass cancer immune evasion. Here, we review recent advances in CAR-T cell therapy for NHL...
May 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29625833/celyad-s-novel-car-t-cell-therapy-for-solid-malignancies
#18
Caroline Lonez, Alain Hendlisz, Leila Shaza, Philippe Aftimos, Michaël Vouche, Vincent Donckier, Jean-Pascal H Machiels, Marc Van Den Eynde, Jean-Luc Canon, Javier Carrasco, Kunle Odunsi, Solmaz Sahebjam, Sylvie Rottey, Nathalie Braun, Bikash Verma, David E Gilham, Frédéric F Lehmann
Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against solid tumors.
May 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29625832/considerations-pertaining-to-cell-collection-and-administration-of-industry-manufactured-autologous-car-t-cells-in-relation-to-french-healthcare-organization-and-regulations
#19
Christian Chabannon, Jérôme Larghero
Access to treatment with CAR-T Cells at European hospitals in general and at French hospitals in particular remains limited, when compared with the situation that prevails in the USA or in certain Asian countries. Multiple reasons explain why European investigators lag behind their US or Chinese colleagues in this clinical research area. Some of these reasons are related to the European and French regulatory landscapes that hamper the design and rapid implementation of organizational solutions needed for safe and efficient administration of CAR-T Cells...
May 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29625831/insights-into-cytokine-release-syndrome-and-neurotoxicity-after-cd19-specific-car-t-cell-therapy
#20
REVIEW
Jordan Gauthier, Cameron J Turtle
T-cells engineered to express CD19-specific chimeric antigen receptors (CD19 CAR-T cells) can achieve high response rates in patients with refractory/relapsed (R/R) CD19+ hematologic malignancies. Nonetheless, the efficacy of CD19-specific CAR-T cell therapy can be offset by significant toxicities, such as cytokine release syndrome (CRS) and neurotoxicity. In this report of our presentation at the 2018 Second French International Symposium on CAR-T cells (CAR-T day), we describe the clinical presentations of CRS and neurotoxicity in a cohort of 133 adults treated with CD19 CAR-T cells at the Fred Hutchinson Cancer Research Center, and provide insights into the mechanisms contributing to these toxicities...
May 2018: Current Research in Translational Medicine
journal
journal
53206
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"